Lifestyle
- Regular exercise
- Moderate alcohol consumption
- Avoidance of hepatotoxic substances
Aspartat-Aminotransferase · ASAT · GOT · SGOT
AST quantifies the enzyme activity involved in amino acid metabolism, particularly in the liver and muscle tissues.
Reference ranges may vary slightly by laboratory; generally similar for both sexes.
Aspartate aminotransferase (AST), also known as glutamate oxaloacetate transaminase (GOT), is an enzyme found in various tissues, including the liver, heart, and muscles. It plays a crucial role in amino acid metabolism by catalyzing the transfer of an amino group from aspartate to alpha-ketoglutarate, forming oxaloacetate and glutamate. Clinically, AST is a significant marker for liver health, as elevated levels often indicate liver damage or inflammation, such as from hepatitis, cirrhosis, or liver cancer. It is also elevated in conditions affecting other organs, such as myocardial infarction or muscle injury. In the context of athletic performance and biohacking, AST levels can reflect muscle damage from intense exercise, providing insight into recovery needs and potential overtraining. However, interpreting AST levels requires caution, as they can be influenced by factors such as recent physical activity, medications, and other health conditions. Researchers have found that fasting and time of day do not significantly impact AST levels, but it is essential to consider these factors when comparing results over time.
Klinische Bedeutung
Elevated AST levels typically indicate liver damage or inflammation but can also reflect muscle injury or myocardial infarction. Low AST levels are less clinically significant but may occur in vitamin B6 deficiency.
Progressively rising AST values suggest worsening liver or muscle damage. Re-test in 4-6 weeks if elevated.
Falling AST values indicate recovery from liver or muscle injury.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if liver disease is suspected.
Test at the same time of day for consistency; levels may vary slightly throughout the day.
Testing Frequency
Annually for healthy adults, more frequently if monitoring liver health.
Current research suggests that reference ranges for AST (GOT) in various populations, particularly in specific disease contexts like leptospirosis and sarcoidosis, remain debated. Researchers have not yet established optimal AST targets for predicting disease severity or outcomes in conditions such as liver fibrosis or invasive infections. Additionally, clinical questions regarding the influence of confounding factors, such as concurrent medications and comorbidities, on AST levels and their interpretation in different clinical scenarios remain unanswered.
476
Total Citations
30
Human/RCT
2.5
Avg. Influence
2025
Latest
This meta-analysis summarized biomarkers associated with the severity of COVID-19. Researchers found that ASAT levels were significantly elevated in severe cases, with an odds ratio of 2.27 indicating increased risk. The study suggests that monitoring liver enzymes like ASAT may aid in prognostic risk stratification for COVID-19 patients.
This review discussed the use of serum enzyme levels, including ASAT, in diagnosing alcohol-related organ damage. Researchers noted that elevated ASAT levels can indicate alcohol-induced liver injury, particularly when the ASAT/ALAT ratio exceeds 1.5. The study emphasizes the variability of enzyme markers in diagnosing organ damage.
Researchers assessed the incidence of hypoxic hepatitis in patients with cardiogenic shock. They found that elevated ASAT levels were an independent predictor of 30-day mortality, with a significant incidence of hypoxic hepatitis observed in the study population. The findings underscore the prognostic relevance of ASAT in these patients.
This study explored the effects of ursodeoxycholic acid (UDCA) on patients with hepatic sarcoidosis. Researchers found that serum liver tests, including ASAT levels, improved in patients treated with UDCA compared to those receiving no treatment or corticosteroids. The findings suggest potential benefits of UDCA for symptomatic patients with liver involvement in sarcoidosis.
This study analyzed clinical and biochemical data from 22 patients with GM1 gangliosidosis. Researchers found that increased ASAT concentrations were present in 65% of the patients, indicating its potential role in the diagnosis of this condition.
Researchers assessed sperm morphology and ASAT release in boars over seven months to relate these factors to fertility. They found that ASAT release was measured in relation to the fertility outcomes of the boars, indicating a potential link between sperm viability and ASAT levels.
Researchers reviewed methodologies for measuring aspartate aminotransferase (ASAT) and proposed a unifying reference system to improve interlaboratory compatibility. They emphasized the need for standardized enzyme reference materials to ensure consistent ASAT results across different laboratories. This approach aims to enhance the reliability of ASAT measurements in clinical settings.
This study analyzed clinical manifestations of leptospirosis in elderly patients. Researchers found that ASAT levels were slightly elevated, indicating hepatic dysfunction, and noted a high mortality rate associated with severe forms of the disease.
This study proposed a protocol for an enhanced cardiac enzyme profile to improve the diagnosis of myocardial injury. Researchers highlighted the usefulness of ASAT and the ASAT/ALAT ratio in evaluating cardiac conditions, particularly when testing occurs later after symptom onset. The protocol aims to streamline enzyme testing for better diagnostic outcomes.
Researchers compared self-reported alcohol consumption questionnaires with laboratory markers for alcohol dependence. They found that ASAT levels, along with other markers, had low sensitivity for diagnosing alcoholism, although they showed high specificity. This study suggests that while alcohol markers can support diagnosis, they may not be reliable screening tools in general hospitals.
1
Total Trials
63
Total Enrolled
Bristol-Myers Squibb
63
2006
Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
Research publications about AST (GOT) over time
10totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer